Reading the map, one question at a time.
Straight answers for clinic owners on sourcing compounded medications — the prescriber requirement, the 503A/503B distinction, how to vet a supplier, and how to read a regulatory market that keeps moving. No fear-selling, no hype. Just the lay of the land, with sources.
What the Blue Atlas application actually asks — and how to breeze through it
What to have ready (NPI, state license, a prescriber on file), what the form asks, the ~2-business-day review, and the common snags — so your application goes through the first time.
Read →Sourcing for chiropractic & integrated practices: the prescriber path
Chiropractic and integrated practices adding wellness services face one specific gate — the prescriber requirement. Why it applies, the two clean paths to a provider on file, and what sourcing looks like once one is in place.
Read →Cold chain, documentation & fulfillment: what to expect after you order
What actually happens between “order placed” and a package on your counter: where it ships, why some preparations ship cold, and the honest version of what documentation to expect.
Read →What a dedicated rep actually does — and why it matters more now
When suppliers look interchangeable, the relationship is the differentiator. What a real rep does — translate a shifting market, catch problems early, stay one accountable point of contact — and why a portal alone can’t replace it.
Read →Second source, not a switch: why smart practices multi-source
You don’t have to leave a supplier you like to work with a new one. Keeping more than one qualified source is standard practice — it protects you from backorders, gaps, and single-vendor risk.
Read →How to read a shifting compounding map — without panic or hype
The rules about what can be compounded really do change — but the changes follow a knowable logic. A calm framework: why the map moves, what stays stable, and how to keep your practice on solid ground.
Read →What “510(k)-cleared” actually means — device clearance vs. drug approval
510(k) clearance is a real FDA status — for a device, not a drug. Blurring the two is how clinics inherit risk. A plain explainer using the Peptide Therapy Pen as the example.
Read →Sermorelin: the compounded peptide you can actually name
Of the peptides clinics ask about, sermorelin has the cleanest regulatory footing to name — because it’s a component of a former FDA-approved drug discontinued for business reasons, not safety or effectiveness.
Read →Do you need a prescriber on file to order compounded medications?
You don’t have to be the prescriber yourself — but your practice needs a licensed provider on file. How the NPI + state-license check works, and what to do if you don’t have a prescriber yet.
Read →How to vet a compounded-medication supplier: 5 questions every clinic should ask
A calm due-diligence checklist you can use on any supplier — mine included. If a source can’t answer these five questions, that’s your answer.
Read →